medscape.com
Cure8 news brief
Vedolizumab Reduces Postoperative Crohn’s Disease Recurrence
Medications
Vedolizumab
Anti Integrin
Bowel Resection
Phase 3 clinical trial
Adult patients
Clinicians
Patients On Biologics
Why This Matters
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing disease return after surgery.
Who Should Pay Attention
Adults with Crohn’s disease who are post-ileocolonic resection, especially those with risk factors for recurrence; patients considering biologic prophylaxis after surgery; gastroenterologists and surgeons managing postoperative IBD care; clinicians interested in non–anti-TNF biologic options.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This randomized trial tested vedolizumab (300 mg IV at weeks 0, 8, 16, 24) versus placebo after ileocolonic surgery in Crohn’s patients with risk factors for recurrence. At 26 weeks, vedolizumab-treated patients had lower endoscopic recurrence by modified Rutgeerts score and fewer cases of severe endoscopic recurrence.
Serious adverse events occurred in a small proportion and were not linked to vedolizumab serum levels.
Decisions about postoperative prophylaxis should still be individualized with your gastroenterologist; this trial provides randomized evidence supporting vedolizumab as an option, especially for people with prior anti-TNF failure or contraindications to anti-TNF therapy.
Read the full Lancet Gastroenterology & Hepatology report (and disclosures) for detailed methods, endpoints, and longer-term follow-up plans if available.
Keep In Mind
The REPREVIO trial had a relatively small sample size and short follow-up (26 weeks for endoscopy). Results are from a published randomized trial reported in The Lancet Gastroenterology & Hepatology and summarized by Medscape; longer-term outcomes and broader confirmatory studies would strengthen confidence before changing standard practice.
Study drug and support were provided by Takeda; review disclosed author relationships.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 3 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmedscape.com
Indexed viaBing News
Source typeResearch news
PublishedDec 26, 2024, 2:54 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.